Published in Proc Natl Acad Sci U S A on August 08, 2011
B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol (2012) 3.69
Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science (2012) 3.53
Highly conserved protective epitopes on influenza B viruses. Science (2012) 3.47
Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci U S A (2012) 3.27
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol (2012) 2.74
Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature (2012) 2.44
Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature (2013) 2.08
Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog (2012) 2.02
H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination. PLoS One (2011) 2.02
Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody. Proc Natl Acad Sci U S A (2012) 1.70
Complex Antigens Drive Permissive Clonal Selection in Germinal Centers. Immunity (2016) 1.66
A recurring motif for antibody recognition of the receptor-binding site of influenza hemagglutinin. Nat Struct Mol Biol (2013) 1.60
Broadly neutralizing antibodies against influenza virus and prospects for universal therapies. Curr Opin Virol (2012) 1.54
Immune history shapes specificity of pandemic H1N1 influenza antibody responses. J Exp Med (2013) 1.47
Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA. Immunol Rev (2012) 1.44
A common solution to group 2 influenza virus neutralization. Proc Natl Acad Sci U S A (2013) 1.34
Tools to therapeutically harness the human antibody response. Nat Rev Immunol (2012) 1.30
Broadly neutralizing antibodies against influenza viruses. Antiviral Res (2013) 1.29
Targeting B cell responses in universal influenza vaccine design. Trends Immunol (2011) 1.27
A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. J Virol (2014) 1.23
Structural vaccinology starts to deliver. Nat Rev Microbiol (2012) 1.22
Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity. Proc Natl Acad Sci U S A (2012) 1.22
Human monoclonal antibodies to pandemic 1957 H2N2 and pandemic 1968 H3N2 influenza viruses. J Virol (2012) 1.20
Influenza human monoclonal antibody 1F1 interacts with three major antigenic sites and residues mediating human receptor specificity in H1N1 viruses. PLoS Pathog (2012) 1.19
The inherent mutational tolerance and antigenic evolvability of influenza hemagglutinin. Elife (2014) 1.18
Structural basis for Marburg virus neutralization by a cross-reactive human antibody. Cell (2015) 1.18
Structure and accessibility of HA trimers on intact 2009 H1N1 pandemic influenza virus to stem region-specific neutralizing antibodies. Proc Natl Acad Sci U S A (2013) 1.17
Immunodominance of antigenic site B over site A of hemagglutinin of recent H3N2 influenza viruses. PLoS One (2012) 1.17
Mechanisms of hemagglutinin targeted influenza virus neutralization. PLoS One (2013) 1.16
Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses. Cell (2016) 1.16
Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages. J Virol (2014) 1.15
Integrating sequence variation and protein structure to identify sites under selection. Mol Biol Evol (2012) 1.15
A human antibody recognizing a conserved epitope of H5 hemagglutinin broadly neutralizes highly pathogenic avian influenza H5N1 viruses. J Virol (2012) 1.15
Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection. Proc Natl Acad Sci U S A (2014) 1.14
Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin. J Virol (2014) 1.13
Antibody recognition of the pandemic H1N1 Influenza virus hemagglutinin receptor binding site. J Virol (2013) 1.12
Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. PLoS Pathog (2015) 1.11
Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strains. J Virol (2013) 1.10
Viral receptor-binding site antibodies with diverse germline origins. Cell (2015) 1.09
Universal immunity to influenza must outwit immune evasion. Front Microbiol (2014) 1.03
Structural characterization of viral epitopes recognized by broadly cross-reactive antibodies. Curr Top Microbiol Immunol (2015) 1.02
N-linked glycosylation in the hemagglutinin of influenza A viruses. Yonsei Med J (2012) 1.01
Identification and structural characterization of a broadly neutralizing antibody targeting a novel conserved epitope on the influenza virus H5N1 hemagglutinin. J Virol (2012) 1.00
Development of Norwalk virus-specific monoclonal antibodies with therapeutic potential for the treatment of Norwalk virus gastroenteritis. J Virol (2013) 0.99
Receptor mimicry by antibody F045-092 facilitates universal binding to the H3 subtype of influenza virus. Nat Commun (2014) 0.99
To dream the impossible dream: universal influenza vaccination. Curr Opin Virol (2013) 0.98
Re-engaging cross-reactive memory B cells: the influenza puzzle. Front Immunol (2012) 0.97
Influenza A virus entry inhibitors targeting the hemagglutinin. Viruses (2013) 0.95
Cross-species comparison of site-specific evolutionary-rate variation in influenza haemagglutinin. Philos Trans R Soc Lond B Biol Sci (2013) 0.95
A unique and conserved neutralization epitope in H5N1 influenza viruses identified by an antibody against the A/Goose/Guangdong/1/96 hemagglutinin. J Virol (2013) 0.94
Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination. Nat Med (2016) 0.93
Alternative recognition of the conserved stem epitope in influenza A virus hemagglutinin by a VH3-30-encoded heterosubtypic antibody. J Virol (2014) 0.93
Cold-adapted pandemic 2009 H1N1 influenza virus live vaccine elicits cross-reactive immune responses against seasonal and H5 influenza A viruses. J Virol (2012) 0.93
Distribution of surface glycoproteins on influenza A virus determined by electron cryotomography. Vaccine (2012) 0.93
Human antibodies that neutralize respiratory droplet transmissible H5N1 influenza viruses. J Clin Invest (2013) 0.92
Conserved neutralizing epitope at globular head of hemagglutinin in H3N2 influenza viruses. J Virol (2014) 0.91
Focused antibody response to influenza linked to antigenic drift. J Clin Invest (2015) 0.89
Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses. J Virol (2016) 0.87
High-throughput identification of loss-of-function mutations for anti-interferon activity in the influenza A virus NS segment. J Virol (2014) 0.87
Structure of a PE-PPE-EspG complex from Mycobacterium tuberculosis reveals molecular specificity of ESX protein secretion. Proc Natl Acad Sci U S A (2014) 0.87
Identification of dominant antibody-dependent cell-mediated cytotoxicity epitopes on the hemagglutinin antigen of pandemic H1N1 influenza virus. J Virol (2013) 0.87
Strategies to guide the antibody affinity maturation process. Curr Opin Virol (2015) 0.87
Key mutations stabilize antigen-binding conformation during affinity maturation of a broadly neutralizing influenza antibody lineage. Proteins (2015) 0.86
Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site. Cell (2015) 0.86
Unraveling of a neutralization mechanism by two human antibodies against conserved epitopes in the globular head of H5 hemagglutinin. J Virol (2012) 0.86
Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses. PLoS Pathog (2016) 0.86
Changes to the dynamic nature of hemagglutinin and the emergence of the 2009 pandemic H1N1 influenza virus. Sci Rep (2015) 0.85
Glycan masking of hemagglutinin for adenovirus vector and recombinant protein immunizations elicits broadly neutralizing antibodies against H5N1 avian influenza viruses. PLoS One (2014) 0.84
Broader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles. PLoS One (2012) 0.84
MAPs: a database of modular antibody parts for predicting tertiary structures and designing affinity matured antibodies. BMC Bioinformatics (2013) 0.83
Crystal structure of the Hendra virus attachment G glycoprotein bound to a potent cross-reactive neutralizing human monoclonal antibody. PLoS Pathog (2013) 0.83
The human side of influenza. J Leukoc Biol (2012) 0.83
OptMAVEn--a new framework for the de novo design of antibody variable region models targeting specific antigen epitopes. PLoS One (2014) 0.82
Options and obstacles for designing a universal influenza vaccine. Viruses (2014) 0.82
Heterosubtypic antibodies to influenza A virus have limited activity against cell-bound virus but are not impaired by strain-specific serum antibodies. J Virol (2014) 0.82
Two Escape Mechanisms of Influenza A Virus to a Broadly Neutralizing Stalk-Binding Antibody. PLoS Pathog (2016) 0.82
Discovery of protective B-cell epitopes for development of antimicrobial vaccines and antibody therapeutics. Immunology (2014) 0.82
Epitope mapping of the hemagglutinin molecule of A/(H1N1)pdm09 influenza virus by using monoclonal antibody escape mutants. J Virol (2014) 0.81
Alleviative Effects of a Kampo (a Japanese Herbal) Medicine "Maoto (Ma-Huang-Tang)" on the Early Phase of Influenza Virus Infection and Its Possible Mode of Action. Evid Based Complement Alternat Med (2014) 0.81
Developing Universal Influenza Vaccines: Hitting the Nail, Not Just on the Head. Vaccines (Basel) (2015) 0.81
Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain. Nat Med (2016) 0.81
HA Antibody-Mediated FcγRIIIa Activity Is Both Dependent on FcR Engagement and Interactions between HA and Sialic Acids. Front Immunol (2016) 0.80
Insight into highly conserved H1 subtype-specific epitopes in influenza virus hemagglutinin. PLoS One (2014) 0.80
Structures of complexes formed by H5 influenza hemagglutinin with a potent broadly neutralizing human monoclonal antibody. Proc Natl Acad Sci U S A (2015) 0.80
Comprehensive analysis of antibody recognition in convalescent humans from highly pathogenic avian influenza H5N1 infection. Nat Commun (2015) 0.80
A broadly neutralizing human monoclonal antibody directed against a novel conserved epitope on the influenza virus H3 hemagglutinin globular head. J Virol (2014) 0.80
Immunogenic Stimulus for Germline Precursors of Antibodies that Engage the Influenza Hemagglutinin Receptor-Binding Site. Cell Rep (2015) 0.79
B Cells and Functional Antibody Responses to Combat Influenza. Front Immunol (2015) 0.79
Rational design of vaccines for AIDS and influenza. Trans Am Clin Climatol Assoc (2012) 0.79
Influenza virus antigenicity and broadly neutralizing epitopes. Curr Opin Virol (2015) 0.79
Cross-protective immune responses elicited by live attenuated influenza vaccines. Yonsei Med J (2013) 0.79
Prospects of HA-based universal influenza vaccine. Biomed Res Int (2015) 0.79
Novel Monoclonal Antibodies for Studies of Human and Rhesus Macaque Secretory Component and Human J-Chain. Monoclon Antib Immunodiagn Immunother (2016) 0.78
Conformational inactivation induces immunogenicity of the receptor-binding pocket of a bacterial adhesin. Proc Natl Acad Sci U S A (2013) 0.78
Max Bergmann lecture protein epitope mimetics in the age of structural vaccinology. J Pept Sci (2013) 0.78
A Simple Flow-Cytometric Method Measuring B Cell Surface Immunoglobulin Avidity Enables Characterization of Affinity Maturation to Influenza A Virus. MBio (2015) 0.78
Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01
Phaser crystallographic software. J Appl Crystallogr (2007) 108.34
Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Res (1998) 96.63
Evolutionary trees from DNA sequences: a maximum likelihood approach. J Mol Evol (1981) 67.56
PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr (2002) 53.61
Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature (1981) 24.17
Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem (2000) 19.03
Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature (1981) 15.85
Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med (2009) 15.02
Version 1.2 of the Crystallography and NMR system. Nat Protoc (2007) 13.01
The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell (1982) 12.44
The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu Rev Biochem (1987) 11.99
Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature (2008) 10.80
Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science (2010) 10.69
The structure and receptor binding properties of the 1918 influenza hemagglutinin. Science (2004) 7.74
Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science (2010) 6.10
Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA (2009) 5.84
Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med (2007) 3.63
Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design. Sci Transl Med (2010) 3.06
High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J Virol Methods (2009) 2.75
An antibody that prevents the hemagglutinin low pH fusogenic transition. Virology (2002) 2.56
Variation and infectivity neutralization in influenza. Immunology (2006) 2.23
Antigen distortion allows influenza virus to escape neutralization. Nat Struct Biol (1998) 1.88
Crystal structure of the swine-origin A (H1N1)-2009 influenza A virus hemagglutinin (HA) reveals similar antigenicity to that of the 1918 pandemic virus. Protein Cell (2010) 1.74
Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies. PLoS Pathog (2011) 1.70
Crystal structure of a non-neutralizing antibody to the HIV-1 gp41 membrane-proximal external region. Nat Struct Mol Biol (2010) 1.24
Chiropteran types I and II interferon genes inferred from genome sequencing traces by a statistical gene-family assembler. BMC Genomics (2010) 1.01
Large-scale analysis of human heavy chain V(D)J recombination patterns. Immunome Res (2008) 1.00
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
A whole-genome association study of major determinants for host control of HIV-1. Science (2007) 15.19
Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 12.98
X-ray structure of a protein-conducting channel. Nature (2003) 9.20
Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science (2005) 9.04
Structure of an unliganded simian immunodeficiency virus gp120 core. Nature (2005) 8.30
Structure of the dengue virus envelope protein after membrane fusion. Nature (2004) 7.97
Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science (2011) 7.92
A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A (2003) 7.76
Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol (2008) 7.54
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature (2011) 7.20
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22
The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol (2009) 5.99
Crystal structure of glycoprotein B from herpes simplex virus 1. Science (2006) 5.57
Lipid-protein interactions in double-layered two-dimensional AQP0 crystals. Nature (2005) 5.44
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature (2012) 5.44
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature (2013) 5.35
Near-atomic resolution using electron cryomicroscopy and single-particle reconstruction. Proc Natl Acad Sci U S A (2008) 5.33
Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science (2005) 4.97
Acute HIV-1 Infection. N Engl J Med (2011) 4.84
Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity (2013) 4.82
The yeast DASH complex forms closed rings on microtubules. Nat Struct Mol Biol (2005) 4.81
Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med (2009) 4.79
Medicine. The need for a global HIV vaccine enterprise. Science (2003) 4.70
The Ndc80/HEC1 complex is a contact point for kinetochore-microtubule attachment. Nat Struct Mol Biol (2006) 4.62
Molecular model for a complete clathrin lattice from electron cryomicroscopy. Nature (2004) 4.48
An atomic model of the interferon-beta enhanceosome. Cell (2007) 4.22
Advantage of rare HLA supertype in HIV disease progression. Nat Med (2003) 4.08
Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol (2011) 4.06
Structure and function of an essential component of the outer membrane protein assembly machine. Science (2007) 3.85
The characterization of twenty sequenced human genomes. PLoS Genet (2010) 3.72
B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol (2012) 3.69
High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog (2010) 3.68
Common genetic variation and the control of HIV-1 in humans. PLoS Genet (2009) 3.68
Structure of the human transferrin receptor-transferrin complex. Cell (2004) 3.64
Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J Virol (2005) 3.58
Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol (2009) 3.36
XMAP215 is a processive microtubule polymerase. Cell (2008) 3.33
HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev (2013) 3.30
Influence of HLA-C expression level on HIV control. Science (2013) 3.27
A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology (2006) 3.26
Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity (2010) 3.25
Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med (2005) 3.19
Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci U S A (2009) 3.19
Identifying differential expression in multiple SAGE libraries: an overdispersed log-linear model approach. BMC Bioinformatics (2005) 3.12
Structure of heptameric protective antigen bound to an anthrax toxin receptor: a role for receptor in pH-dependent pore formation. Proc Natl Acad Sci U S A (2004) 3.10
Statistical mixture modeling for cell subtype identification in flow cytometry. Cytometry A (2008) 3.06
Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. PLoS One (2010) 3.02
Molecular organization of the Ndc80 complex, an essential kinetochore component. Proc Natl Acad Sci U S A (2005) 3.01
Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J Virol (2005) 2.89
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis (2012) 2.89
Beam-induced motion of vitrified specimen on holey carbon film. J Struct Biol (2012) 2.84
Movies of ice-embedded particles enhance resolution in electron cryo-microscopy. Structure (2012) 2.80
Pathway level analysis of gene expression using singular value decomposition. BMC Bioinformatics (2005) 2.78
Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci U S A (2013) 2.75
MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med (2011) 2.75
High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J Virol Methods (2009) 2.75
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol (2012) 2.74
RNA synthesis in a cage--structural studies of reovirus polymerase lambda3. Cell (2002) 2.74
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A (2013) 2.69
Wide variation in the multiplicity of HIV-1 infection among injection drug users. J Virol (2010) 2.67
Molecular interactions in rotavirus assembly and uncoating seen by high-resolution cryo-EM. Proc Natl Acad Sci U S A (2009) 2.65
Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A (2012) 2.59
Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J Virol (2011) 2.55
Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS (2009) 2.53
Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med (2010) 2.53
Subunit interactions in bovine papillomavirus. Proc Natl Acad Sci U S A (2010) 2.51
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med (2014) 2.47